CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Vasa - European Journal of Vascular Medicine is a leading peer-reviewed journal dedicated to advancing the field of vascular medicine, published by HOGREFE AG in Switzerland. With a proud history dating back to 1972, this journal serves as a critical platform for researchers, clinicians, and healthcare professionals committed to enhancing knowledge and practice related to cardiovascular health and vascular disorders. Holding a notable Q2 ranking in the cardiology and cardiovascular medicine category, Vasa’s scholarly contributions reflect high-quality research and innovative insights that drive clinical applications. The journal provides essential access to original articles, reviews, and case studies, fostering a vibrant exchange of ideas within the vascular medicine community. Its Scopus rank of #159 out of 387 further underscores its impact, placing it confidently in the 59th percentile among its peers. Vasa is synonymous with rigorous academic standards and relevance, making it an invaluable resource for anyone seeking to stay at the forefront of vascular research and its clinical implications.

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.

Vascular Medicine is a premier academic journal for researchers and practitioners in the field of cardiovascular health, published by SAGE Publications Ltd. With an ISSN of 1358-863X and E-ISSN 1477-0377, this esteemed journal has been at the forefront of publishing quality research since its inception in 1992, with convergence extending to 2024. Ranked in the Q2 category for both Cardiology and Cardiovascular Medicine as well as for miscellaneous Medicine in 2023, it is recognized for its significant contributions to advancing knowledge and clinical practice within these domains. Its Scopus ranking situates it at #91 out of 387 in the field, reflecting its high impact and the relevance of its published research, which is crucial for addressing the challenges in vascular health today. Although it is not an open-access journal, Vascular Medicine remains dedicated to disseminating vital findings that bridge the gap between research and clinical application, making it an essential resource for medical researchers, healthcare professionals, and students alike.

Acta Angiologica, published by VIA MEDICA, is an Open Access journal dedicated to the dynamic field of cardiology and cardiovascular medicine. Since its inception in 1995, this esteemed journal has provided a vital platform for the dissemination of cutting-edge research and innovative medical practices, especially pertinent to vascular health. Being indexed in Scopus, it holds a rank of #352 out of 387 in its category for 2023, positioning it in the 9th percentile among contemporaneous journals. The journal's commitment to scholarly excellence and accessibility is underscored by its embrace of open access publishing, allowing researchers, professionals, and students to engage with vital advancements in the field without financial barriers. With a converged timeline from 2005 to 2024, Acta Angiologica continues to play a crucial role in bridging gaps in cardiovascular knowledge, fostering collaboration across disciplines, and advancing the implementation of preventative and therapeutic strategies in vascular medicine. Located in Gdansk, Poland, the journal is poised to make significant contributions to the cardiovascular research landscape.

Welcome to the JOURNAL OF VASCULAR RESEARCH, a reputable academic journal published by KARGER that has been a cornerstone of vascular research since 1964. With an ISSN of 1018-1172 and an E-ISSN of 1423-0135, this journal plays a vital role in disseminating cutting-edge research in the fields of Cardiology and Cardiovascular Medicine and Physiology. Currently categorized in the Q3 quartile for both disciplines, it ranks as #179 in Cardiology and #131 in Physiology according to Scopus, showcasing its significant contribution to the scientific community. Although the journal operates on a subscription basis, it strives to provide accessible content that informs and inspires researchers, professionals, and students alike. As the journal looks forward to its convergence in 2024, it continues to uphold its mission of advancing knowledge, fostering innovation, and encouraging collaboration within the dynamic realm of vascular research.

Diabetes & Vascular Disease Research is a leading academic journal dedicated to advancing the understanding and treatment of cardiovascular and metabolic diseases, particularly diabetes. Published by SAGE Publications Ltd in the United Kingdom, this journal serves as a key resource for researchers, clinicians, and students seeking to explore the intricate relationship between diabetes and vascular health. With an impressive Impact Factor and ranked in the Q2 quartile in prominent categories such as Cardiology, Endocrinology, and Internal Medicine, the journal provides a platform for high-quality, peer-reviewed research. Covering a broad range of topics from pathophysiology to therapeutic innovations, Diabetes & Vascular Disease Research plays a vital role in shaping contemporary discourse in the field. With contributions from leading experts and a commitment to disseminating valuable findings, this journal is a must-read for anyone involved in the fight against vascular complications arising from diabetes.

Arterial Hypertension is a dedicated Open Access journal published by VIA MEDICA, with the ISSN 2449-6170 and E-ISSN 2449-6162, focusing on the multidisciplinary field of cardiology, endocrinology, and internal medicine. Established in Poland, this journal has been providing researchers and healthcare professionals with accessible, high-quality content since its inception in 1999. With a commitment to advancing knowledge in the management and treatment of arterial hypertension, it publishes significant research findings, clinical trials, and reviews that contribute to improved health outcomes. Though classified in Q4 across various relevant categories, the continuous improvement in its content ensures its relevance in an evolving medical landscape. Designed to facilitate collaboration and innovation, Arterial Hypertension serves as a crucial resource for anyone invested in cardiovascular health, encouraging open dialogue and dissemination of vital research within the scientific community.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.